Results 101 to 110 of about 48,845 (222)

Bifunktionale Cosubstrate ermöglichen Threonin‐Dehydrogenase katalysierte chemoenzymatische Pyrrolsynthese

open access: yesAngewandte Chemie, Volume 138, Issue 46, 9 November 2026.
Klassische Knorr‐Chemie trifft auf moderne Biokatalyse. Die Threonindehydrogenase erzeugt aus l‐Threonin Aminoaceton, welches direkt in einer chemoenzymatischen Knorr‐Pyrrolsynthese abgefangen wird. Ein bifunktionales β‐Dicarbonylsubstrat dient sowohl als Pyrrolbaustein als auch als Hydridakzeptor für integrierte NAD+‐Recyclierung und ermöglicht die ...
Valentina Jurkaš   +8 more
wiley   +1 more source

Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial

open access: yes, 2013
PURPOSE: Open-label, phase III trial evaluating whether sunitinib was superior or equivalent to sorafenib in hepatocellular cancer. PATIENTS AND METHODS: Patients were stratified and randomly assigned to receive sunitinib 37.5 mg once per day or ...
정현철
core   +1 more source

Dual‐Function Cosubstrates Enable Threonine Dehydrogenase‐Driven Chemoenzymatic Pyrrole Synthesis

open access: yesAngewandte Chemie International Edition, Volume 65, Issue 46, 9 November 2026.
Classical Knorr chemistry meets contemporary biocatalysis. Threonine dehydrogenase generates aminoacetone from l‐threonine, which is directly intercepted in a chemoenzymatic Knorr pyrrole synthesis. A dual‐function β‐dicarbonyl substrate serves as both pyrrole precursor and hydride acceptor for integrated NAD+ recycling, affording substituted pyrroles ...
Valentina Jurkaš   +8 more
wiley   +1 more source

Ovarian reserve evaluation after sunitinib or vehicle treatment.

open access: yes, 2016
A. Expression of ovarian Amh transcripts normalized to 18S RNA in mice treated by sunitinib (n = 15) compared with control mice (n = 12 ...
Nadège Carré (542711)   +7 more
core   +1 more source

Organoids in pediatric cancer research

open access: yesFEBS Letters, Volume 600, Issue 21, Page 3221-3240, November 2026.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Sunitinib Induced Thrombotic Thrombocytopenic Purpura in addition to Severe Hypothyroidism: A Case Report and Review of the Literature

open access: yesCase Reports in Medicine, 2014
Introduction. Sunitinib malate is an oral multitargeting tyrosine kinase inhibitor approved for the first line treatment of metastatic renal cell carcinoma.
Imane El Dika   +4 more
doaj   +1 more source

Sunitinib Produces Neuroprotective Effect Via Inhibiting Nitric Oxide Overproduction

open access: yes, 2014
BACKGROUND: Sunitinib is an inhibitor of the multiple receptor tyrosine kinases (RTKs) for cancer therapy. Some sunitinib analogues could prevent neuronal death induced by various neurotoxins.
Choi, CL   +21 more
core   +1 more source

A Unified Hierarchical Multiscale Fusion Framework for Drug–Target Affinity Prediction: From Benchmark Performance to Nanomolar Inhibitor Discovery

open access: yesAdvanced Science, Volume 13, Issue 63, 12 November 2026.
A multimodal fusion framework integrating sequence, atomic, and fragment representations captures drug–target interactions across multiple scales. The model delivers strong predictive performance and enables efficient virtual screening. Applied to hematopoietic progenitor kinase 1 (HPK1), it identifies structurally diverse inhibitors with nanomolar ...
Shuo Liu   +7 more
wiley   +1 more source

The effects of sunitinib on endometriosis

open access: yes, 2015
The aim of the present study was to evaluate the effect of sunitinib on endometriotic implants and adhesions in a rat endometriosis model. An experimental endometriosis model was created in 21 rats.
Pala, H. G.   +10 more
core   +1 more source

Pembrolizumab Activity in Tyrosine Kinase Inhibitor–Refractory Metastatic GIST: A Case Report

open access: yesCancer Reports, Volume 9, Issue 11, November 2026.
ABSTRACT Introduction Gastrointestinal stromal tumors (GISTs) are commonly driven by activating mutations in KIT or PDGFRA. Although sequential tyrosine kinase inhibitors (TKIs) have improved outcomes in advanced disease, acquired resistance is common.
Neharika Bandaru   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy